{"nctId":"NCT00297115","briefTitle":"Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)","startDateStruct":{"date":"2006-03"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"count":1568,"armGroups":[{"label":"Roflumilast","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Roflumilast"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Roflumilast","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* COPD patients having at least one exacerbation within last year\n* FEV1/FVC ratio (post-bronchodilator) ≤ 70%\n* FEV1 (post-bronchodilator) ≤ 50% of predicted\n\nMain Exclusion Criteria:\n\n* COPD exacerbation not resolved at first baseline visit\n* Diagnosis of asthma and/or other relevant lung disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)","description":"Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \\[L\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":"7"},{"groupId":"OG001","value":"-25","spread":"7"}]}]}]},{"type":"PRIMARY","title":"COPD Exacerbation Rate (Moderate or Severe)","description":"Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \\[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\\].","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.210","spread":null},{"groupId":"OG001","value":"1.485","spread":null}]}]}]},{"type":"SECONDARY","title":"Post-bronchodilator FEV1 [L]","description":"Mean change from baseline during the treatment period in post-bronchodilator FEV1 \\[L\\]","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":"7"},{"groupId":"OG001","value":"-17","spread":"7"}]}]}]},{"type":"SECONDARY","title":"Time to Mortality Due to Any Reason","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"201.0","spread":"116.9"},{"groupId":"OG001","value":"214.6","spread":"137.3"}]}]}]},{"type":"SECONDARY","title":"Natural Log-transformed C-reactive Protein (CRP)","description":"Mean change from baseline to the last post randomization measurement in natural log-transformed CRP","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0840","spread":null},{"groupId":"OG001","value":"1.0233","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period","description":"The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.662","spread":"0.087"},{"groupId":"OG001","value":"0.376","spread":"0.084"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":157,"n":778},"commonTop":["Diarrhoea","Weight decreased","Nasopharyngitis"]}}}